Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
6,140
Employees6,140
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
6,140
Employees6,140

NTRA Key Statistics

Market cap
58.46B
Market cap58.46B
Price-Earnings ratio
-295.16
Price-Earnings ratio-295.16
Dividend yield
—
Dividend yield—
Average volume
1.22M
Average volume1.22M
High today
$407.88
High today$407.88
Low today
$400.67
Low today$400.67
Open price
$404.71
Open price$404.71
Volume
256.98K
Volume256.98K
52 Week high
$437.41
52 Week high$437.41
52 Week low
$181.00
52 Week low$181.00

Stock Snapshot

Natera(NTRA) stock is priced at $405.54, giving the company a market capitalization of 58.46B. It carries a P/E multiple of -295.16.

As of 2026-10-26, Natera(NTRA) stock has fluctuated between $400.67 and $407.88. The current price stands at $405.54, placing the stock +1.2% above today's low and -0.6% off the high.

The Natera(NTRA)'s current trading volume is 256.98K, compared to an average daily volume of 1.22M.

In the last year, Natera(NTRA) shares hit a 52-week high of $437.41 and a 52-week low of $181.00.

In the last year, Natera(NTRA) shares hit a 52-week high of $437.41 and a 52-week low of $181.00.

NTRA News

Simply Wall St 1h
Natera Partners In Colorectal Cancer, Is The Stock Fully Valued?

Advertisement Why this new colorectal cancer alliance matters for Natera stock Natera (NTRA) just announced a colorectal cancer collaboration with TransCode T...

The Motley Fool 14h
Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree.

It can pay to follow the investing legends. That is why investors take a good, hard look at the portfolio of Stanley Druckenmiller, a hedge fund legend who has...

Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree.
Simply Wall St 3d
Will FDA Breakthrough Status Change Natera Stock Narrative

Natera reported that its multi cancer early detection assay received FDA Breakthrough Device designation, following review of performance data across 12 tumor t...

Analyst ratings

88%

of 25 ratings
Buy
88%
Hold
8%
Sell
4%

More NTRA News

TipRanks 3d
Natera initiated with a Buy at Roth Capital

Roth Capital last night initiated coverage of Natera (NTRA) with a Buy rating and $475 price target The company offers an “unmatched catalyst runway” in oncolog...

Investor's Business Daily 4d
IBD Stock Of The Day, Natera, Hovering Near Buy Point

IBD Stock Of The Day IBD Stock Of The Day, Natera, Hovering Near Buy Point Licensing Natera Natera NTRA $ 400.98 $12.40 3% 7% IBD Stock Analysis Stock pausing a...

IBD Stock Of The Day, Natera, Hovering Near Buy Point

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.